Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01245426 | A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1) | PHASE2 | COMPLETED | 136 | — | — | Dec 1, 2010 | Aug 1, 2011 | Dec 1, 2016 | 11 | Bulgaria, Germany +1 |
| Arm | Type | Description |
|---|---|---|
| GW870086 2mg | EXPERIMENTAL | GW870086 2mg once daily in the morning for 27 ± 2 days |
| GW870086 4mg | EXPERIMENTAL | GW870086 4mg once daily in the morning for 27 ± 2 days |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily in the morning for 27 ± 2 days |
| GW870086 1mg | EXPERIMENTAL | GW870086 1mg once daily in the morning for 27 ± 2 days |
| GW870086 3mg | EXPERIMENTAL | GW870086 3mg once daily in the morning for 27 ± 2 days |
| Name | Type | Description |
|---|---|---|
| GW870086 2mg | DRUG | oral inhalation |
| GW870086 4mg | DRUG | oral inhalation |
| GW870086 Placebo | DRUG | oral inhalation |
| GW870086 1mg | DRUG | oral inhalation |
| GW870086 3mg | DRUG | oral inhalation |
Inclusion Criteria: * Male or female between 18 and 65 years * A female subject is eligible to participate if she is of: Non-childbearing potential. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to discontinue HRT to allow confirmation of post...